Kamari Pharma is a clinical stage biotechnology company developing “first and best in class”
treatments of rare and severe genetic skin diseases, such as Keratoderma and Ichthyosis.

TRPV3 has been recently recognized as a target for drug development and showed involvement in various skin disorders. Kamari is harnessing the therapeutic potential of TRPV3 in order to treat Olmsted Syndrome, Keratodermas, severe chronic itch conditions and Ichthyosis.

Our management team is comprised of individuals with vast experience in drug discovery and pharmaceutical development in the biotech industry, with focus on skin disorders and rare disease. We are supported by clinical and scientific advisors who are world-class key opinion leaders. Our board of directors has a proven track record of success in advancing therapies to treat both rare diseases and skin conditions.